E4ORF1+ ETV2+ Engineered Endothelial Cells for Serum-Free HSPC Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods do not effectively utilize ETV2 transcription factor effects on differentiated endothelial cells or enhance their ability to support the expansion of hematopoietic stem and progenitor cells, particularly in serum-free conditions.
Innovation Solution
Engineering endothelial cells to express both adenovirus E4ORF1 and ETV2 transcription factor, which allows for the maintenance and expansion of endothelial cells and the selective expansion of more primitive hematopoietic stem and progenitor cells in co-culture.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endothelial cells are cultured in serum-free conditions, then cell purity and control are improved, but cell survival and proliferation deteriorate
Solution Approach 1:
The patent introduces ETV2 transcription factor as an intermediary molecule that mediates between serum-free conditions and endothelial cell survival. ETV2 acts as a biochemical mediator that compensates for the absence of serum components, enabling cells to survive and proliferate without serum while maintaining culture control.
Solution Approach 2:
The patent changes the biochemical parameter of cell culture by introducing ETV2 expression to replace serum-dependent growth mechanisms. This parameter change allows the system to function in serum-free conditions by altering the molecular environment through transcription factor expression.
2Reliability
If E4ORF1 is expressed in endothelial cells, then cell survival is improved, but the ability to support primitive HSPC expansion is insufficient
Solution Approach 1:
The patent merges two separate functions into a single engineered endothelial cell system: E4ORF1 expression for endothelial cell survival and ETV2 expression for HSPC expansion support. This combination creates a synergistic system where both functions are achieved simultaneously in one cell type.
Solution Approach 2:
The engineered endothelial cells achieve multi-functionality by expressing both E4ORF1 and ETV2, enabling them to simultaneously support their own survival and promote primitive HSPC expansion. This universal system replaces the need for separate culture conditions for different cell types.
3Reliability
If ETV2 is expressed alone in endothelial cells, then endothelial cell function is maintained, but support for primitive HSPC expansion is limited
Solution Approach 1:
The patent combines ETV2 expression with E4ORF1 expression in the same endothelial cells, merging endothelial cell maintenance function with enhanced HSPC expansion capability. This combination resolves the limitation of ETV2 alone by adding the survival-promoting E4ORF1 function.
Data Source
AI summary
In some aspects the present invention relates to engineered endothelial cells, such as E40RF1+ ETV2+ engineered endothelial cells. In other aspects the present invention relates to methods of making such engineered endothelial cells, and methods of using such engineered endothelial cells, for example in co-culture applications.